ALXN1210-TMA-315: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with a Trigger.01/15/2022 - 01/14/2025 (PI)
Alexion Pharmaceuticals
Atypic Hemolytic Uremic Syndrome (aHUS)03/17/2017 - 03/17/2019 (PI)
Alexion Pharmaceuticals